ArticleCancer medicine2026
Preoperative Co-Mutation of BRAF
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe individual prognostic impacts of BRAF
objectiveTo evaluate the clinicopathological features and recurrence risk associated with the combined BRAF
methodsThis retrospective study included 756 PTC patients. Mutations were detected from preoperative fine-needle aspiration (FNA) samples. Patients were stratified into three groups: double wild-type (BRAF-/TERT-, n = 121), BRAF-mutant only (BRAF+/TERT-, n = 606), and both-mutant (BRAF+/TERT+, n = 27). Clinicopathological comparisons used appropriate statistical tests. Risk factors for extrathyroidal extension (ETE) and high nodal burden (NLNM ≥ 5) were analyzed via univariate and multivariate logistic regression. Recurrence-free survival (RFS) was assessed by Kaplan-Meier analysis and log-rank test.
resultsThe BRAF+/TERT+ group exhibited the most aggressive phenotype: older age (mean 55.2 vs. 41.9-42.7 years, p < 0.001), larger tumors (median 20.0 vs. 8.7-9.3 mm, p < 0.001), highest rates of ETE (85.2% vs. 10.7%-14.0%, p < 0.001), and heaviest nodal burden (NLNM ≥ 5: 63.0% vs. 25.4%-31.4%, p < 0.001). In multivariate analysis, the double-mutant status was the strongest independent risk factor for both ETE (OR = 11.35; p < 0.001) and NLNM ≥ 5 (OR = 8.02; p = 0.044). With a median follow-up of 27 months, Kaplan-Meier analysis revealed a significantly inferior RFS for the BRAF+/TERT+ group compared to the others (log-rank p < 0.001). In contrast, the only BRAF-mutant group exhibited fewer aggressive features, primarily associated with a higher body mass index (BMI) and lower prevalence of Hashimoto's thyroiditis.
conclusionBRAF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.